Westfield Capital Management CO LP Sage Therapeutics, Inc. Transaction History

Westfield Capital Management CO LP

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2021 May 14, 2021	SELL	$70.65 - $96.76 $25 Million - $34.2 Million	-353,603 Closed	0 $0
Q4 2020 Feb 12, 2021	SELL	$58.41 - $89.06 $11.8 Million - $18 Million	-201,870 Reduced 36.34%	353,603 $30.6 Million
Q3 2020 Nov 13, 2020	SELL	$41.13 - $62.45 $287,251 - $436,150	-6,984 Reduced 1.24%	555,473 $34 Million
Q2 2020 Aug 13, 2020	BUY	$25.95 - $43.15 $3.52 Million - $5.86 Million	135,765 Added 31.82%	562,457 $23.4 Million
Q1 2020 May 14, 2020	BUY	$26.15 - $77.24 $4.69 Million - $13.9 Million	179,483 Added 72.6%	426,692 $12.3 Million
Q4 2019 Feb 13, 2020	BUY	$60.18 - $154.77 $6.03 Million - $15.5 Million	100,248 Added 68.21%	247,209 $17.8 Million
Q3 2019 Nov 08, 2019	BUY	$140.29 - $189.96 $20.6 Million - $27.9 Million	146,961 New	146,961 $20.6 Million

198

46.5M

402K

209K

Ticker SAGE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,422,300
Market Cap $323M
Description
Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines to treat central nervous system disorders. Its lead product candidate is ZULRESSO, an intravenous formulation of brexanolone for the treatment of postpartum depression (PPD) in adults. The company's product pipeline also includes zuranolone, a neuroactive...

Get notified when there are updates to the investment portfolio of Westfield Capital Management CO LP, based on Form 13F filings with the SEC.

Stay updated on Westfield Capital Management CO LP with notifications on news.